FOXO4-DRI
Educational information only — not medical advice. Many listed compounds are not FDA-approved for human use. Consult a licensed clinician before starting, changing, or stopping any protocol.
Overview
FOXO4-DRI is an experimental peptide in the senolytic class — compounds studied for their ability to selectively eliminate senescent cells. Senescent cells have permanently stopped dividing but resist normal programmed death, and they accumulate in tissues with age while secreting pro-inflammatory signals thought to contribute to age-related decline.
The peptide was introduced in a widely cited 2017 study in which a FOXO4-based peptide was designed to interfere with the FOXO4-p53 interaction that senescent cells rely on to stay alive. It is a D-retro-inverso version of the sequence, a modification intended to improve stability.
Most of the evidence to date comes from cell cultures and animal models. Human clinical data is very limited, and FOXO4-DRI is not approved by any major regulator for therapeutic use.
How it works
Senescent cells are reported to maintain elevated levels of the FOXO4 protein, which binds and sequesters p53 — a key regulator of cell death — and keeps these cells from undergoing apoptosis. In preclinical work, FOXO4-DRI is described as competitively disrupting this FOXO4-p53 interaction, freeing p53 and directing the senescent cell toward self-destruction.
Because healthy cells are reported not to depend on this same FOXO4-p53 binding for survival, the intended effect is selective clearance of senescent cells while sparing normal ones. This selectivity is the central hypothesis behind the compound, though the precise mechanism and its relevance in humans are not established.
Reported benefits
- Selective clearance of senescent cells in laboratory and animal models
- Improvements in fitness, kidney function, and fur density reported in aged mice
- Reduced chemotherapy-associated toxicity in animal studies
- Studied as a potential tool for reducing senescent-cell burden in tissue-engineering contexts
These are reported findings from preclinical research, not established outcomes in humans.
Considerations & side effects
FOXO4-DRI is an emerging, largely preclinical compound. Because rigorous human trials are lacking, its safety profile, effective use, and long-term effects in people are not characterized. Senolytic mechanisms that induce cell death also raise theoretical concerns that have not been resolved in human studies.
Material sold in the research-chemical market varies in purity and is not manufactured to pharmaceutical standards. FOXO4-DRI is not a treatment and is not a substitute for evaluation and care by a qualified clinician.
Frequently asked
What is FOXO4-DRI?
An experimental senolytic peptide — a modified form of a fragment of the FOXO4 protein — studied for its ability to selectively trigger the death of senescent 'zombie' cells that accumulate with age.
Is FOXO4-DRI FDA-approved?
No. FOXO4-DRI is not approved by the FDA or any major regulator for human use. It remains an experimental compound studied in laboratory and animal models and is sold for research purposes only.
What does 'senolytic' mean?
A senolytic is an agent studied for its ability to selectively clear senescent cells — cells that have stopped dividing but resist dying and can release inflammatory signals into surrounding tissue.
What does the 'DRI' stand for?
D-Retro-Inverso, a chemical modification that reverses the sequence and uses mirror-image D-amino acids. In the original research this was intended to improve the peptide's stability compared with the unmodified sequence.
Is the human evidence established?
No. The most-cited findings come from cell and animal studies. Human clinical data is very limited, so its effects and long-term safety in people are not established.
References
Related compounds
An oral Khavinson peptide bioregulator (peptide complex A-8) targeting the pineal gland — the oral-capsule analog to the injectable Epithalon lineage. The most-studied compound in the Khavinson framework, tied to melatonin, circadian rhythm, and anti-aging research.
Synthetic tetrapeptide that stimulates telomerase production. May support cellular longevity and immune function.
Growth Differentiation Factor 11, a TGF-beta superfamily protein popularized by parabiosis ('young blood') studies suggesting it reverses age-related decline. Findings remain controversial, as early assays could not distinguish it from myostatin. Research-only.